We are interested in the fundamental mechanisms that drive the initiation, development, and progression of hematologic malignancies. Myeloproliferative neoplasms (MPNs) are clonal disorders typified by genetic alterations that activate JAK-STAT signaling. A major focus of the laboratory is to utilize single cell mass cytometry (CyTOF) to characterize dysregulated cytokine signaling networks in MPNs. For these efforts we work in conjunction with the Immunomonitoring Laboratory (IML) within the Center for Human Immunology and Immunotherapy Programs, which houses two CyTOF mass cytometers. Potential projects may also utilize a recently acquired Hyperion imaging mass cytometer that couples high dimensional single cell analysis with spatial localization.
We utilize human patient samples as well as mouse models to interrogate altered signaling pathways in MPN pathogenesis. A major area of interest in the lab is to utilize genetic models to understand the role of inflammatory cytokine signaling in MPNs. A second area of interest is the application of next generation sequencing technologies to delineate genomic complexity and clonal evolution in MPNs. We also utilize patient-derived iPSCs and CRISPR site-directed gene editing to model human MPN pathogenesis. The long-term objective is to integrate these approaches so that phenotype can be connected to underlying genotype. Ultimately, we seek to translate this work into improved therapies for MPN patients.
Applicants interested in cancer biology, signal transduction, genomics, immunology, hematopoiesis, leukemia, and/or stem cells are encouraged to apply.
Please see the following links for additional information:
Applicants must have a Ph.D. and/or M.D. degree and a strong background in cell and molecular biology. Prior experience with flow cytometry, bioinformatics, genomics, and/or mouse models is highly desirable. Strong written and verbal communications skills are essential.
Please send an inquiry and C.V. with list of references to Dr. Oh at firstname.lastname@example.org.